OpenAI launched GPT-Rosalind, a research preview model aimed at accelerating drug discovery and pulling insights from large scientific datasets. Initial enterprise users include Amgen, Moderna, and the Allen Institute, putting OpenAI in direct competition with Google in AI-driven biomedicine. The model marks OpenAI's most explicit push into life sciences to date.

TLDR by @Benthic

More on Launch

Comments